.Attribute Medicine, Released online: 16 September 2024 doi:10.1038/ s41591-024-03244-8In the empirical SCRUM-Japan GOZILA research, after a typical consequence of 11 months, patients along with metastatic intestinal lumps that received biomarker-matched therapies based upon spreading lump DNA profiling revealed a greater professional advantage than those receiving unrivaled treatment.